EMA Authorised: Pepaxti (Melphalan flufenamide hydrochloride) — Oncopeptides AB (publ)

View source ↗

Summary

The European Medicines Agency authorised Pepaxti (melphalan flufenamide hydrochloride) for multiple myeloma, with Oncopeptides AB (publ) as the marketing author…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pepaxti (melphalan flufenamide hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Oncopeptides AB (publ). Decision date: 09/01/2025